Breaking through resistance in mCRPC: Enzalutamide analogues as effective anticancer agents for enhanced male survival
To alleviate metastatic castration-resistant prostate cancer (mCRPC), enzalutamide, a non-steroidal antiandrogen, is employed. Following androgen deprivation therapy or anti-androgen treatment, compensatory mechanisms in prostate cancer have been identified, leading to increased expression and funct...
| Main Authors: | , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Elsevier
2023-12-01
|
| Series: | Results in Chemistry |
| Subjects: | |
| Online Access: | http://www.sciencedirect.com/science/article/pii/S221171562300382X |